Skip to main content
Premature death in RA still exists, and varies according to race/ethnicity demographic groups

Nationwide US CDC's MCoD

Aurelie Najm AurelieRheumo

1 year 3 months ago
Premature death in RA still exists, and varies according to race/ethnicity demographic groups Nationwide US CDC's MCoD database analysis -Mortality rates 11x higher American Indians 3x higher Black or African American people -Median age at death with RA 9-10 years younger https://t.co/FTRWPk7Wz0
#MITIGATE subgroup analysis: Inebilizumab reduced flares & boosted remission across all #IgG4-RD subgroups. HR for f

Mrinalini Dey DrMiniDey

1 year 3 months ago
#MITIGATE subgroup analysis: Inebilizumab reduced flares & boosted remission across all #IgG4-RD subgroups. HR for flare vs PBO: 0.12-0.16 across sex/race. Similar results for all subgroups in achieving flare-free, treatment-free complete remission. @RheumNow #EULAR2025 #OP0189
RA-related premature mortality highest in American Indians--> 3.6x odds of death in <65 vs White peers, w/ no impr

Mrinalini Dey DrMiniDey

1 year 3 months ago
RA-related premature mortality highest in American Indians--> 3.6x odds of death in <65 vs White peers, w/ no improvement over 22 yrs. COVID widened the gap. Need to address structural & social drivers of early death in RA, & wider health disparities. @RheumNow #EULAR2025 #OP0197
Yes, it is relevant to ask patients about physical joint strain in RA and propose strain specific interventions

In ACPA

Aurelie Najm AurelieRheumo

1 year 3 months ago
Yes, it is relevant to ask patients about physical joint strain in RA and propose strain specific interventions In ACPA+ RA pts for each 10% increase in strain, 7% increase in SJC44 and 5% MRI inflammation POS0166 #EULAR2025 @RheumNow https://t.co/jwpi7S8JTW
We should address patients anxiety at RA diagnosis:

cohort 250+ newly diagnosed RA pts
-49% reported anxiety
-41% by 3

Aurelie Najm AurelieRheumo

1 year 3 months ago
We should address patients anxiety at RA diagnosis: cohort 250+ newly diagnosed RA pts -49% reported anxiety -41% by 3 months Anxiety asso w/ CDAI, PROs and 3-5 fold increase in prescription of bio/tsDMARDs Analysis reasonably adjusted POS0163 #EULAR2025 @RheumNow https://t.co/2gejEkRQhO
BioDMARDs reduce polyimmunity in RA

Danish Registry based cohort study 5 yrs follow up
25000+ pts

Polyimmunity in csDM

Aurelie Najm AurelieRheumo

1 year 3 months ago
BioDMARDs reduce polyimmunity in RA Danish Registry based cohort study 5 yrs follow up 25000+ pts Polyimmunity in csDMARDs treated group 2.2% vs. 1.7% in bioDMARDs group HR 0.74 Most frequent autoimmune thyroid disease POS0161 #EULAR2025 @RheumNow https://t.co/9T0mhoUuqs
In D2T-PsA (10%), 57% had persistent inflammation (PIPsA), 43% non-inflammatory (NIPsA). Ultrasound distinguished phenot

Antoni Chan MD (Prof) synovialjoints

1 year 3 months ago
In D2T-PsA (10%), 57% had persistent inflammation (PIPsA), 43% non-inflammatory (NIPsA). Ultrasound distinguished phenotypes: median US activity score 3.22 vs 0.88.,swollen joints 2.5 vs 0, tender points higher in NIPsA. Abstract OP0176 @RheumNow #EULAR2025 https://t.co/k7m8gAzbAZ
Nordic registries (n=13,872): D2T-PsA varied 37% (≥2 b/tsDMARDs failed) to 0.6% (strictest). Female predominance incre

Antoni Chan MD (Prof) synovialjoints

1 year 3 months ago
Nordic registries (n=13,872): D2T-PsA varied 37% (≥2 b/tsDMARDs failed) to 0.6% (strictest). Female predominance increased with therapy failures (≥4 failures: 67% female). Median time to failure: 5–7 years. Abstract OP0177 @RheumNow #EULAR2025 https://t.co/lchPnTCEx7
Psoriatic Arthritis: Hit hard and Early
  • EurekAlert!
Two recent studies suggest there is no significant benefit of early biologics over standard step-up care with methotrexate2,3, but these did not select for poor prognosis.
There is still hope for vagal nerve stimulation in RA!
RCT RESET-RA 240+pts multibioIR
Implantable cervical device
Meet

Aurelie Najm AurelieRheumo

1 year 3 months ago
There is still hope for vagal nerve stimulation in RA! RCT RESET-RA 240+pts multibioIR Implantable cervical device Meets Primary endpoint ACR 20 wk12 Subgroup 1 prior bioDMARD ACR 20 wk12 46% vs 19% sham EULAR Good response 61% vs 42% sham Wk 12 SAE rate 1.7% #OP0190 #EULAR2025 https://t.co/DCON01XXgd
2-year #MANDARA data: Benralizumab shows durable remission, eosinophil suppression & OGC-sparing in EGPA. ~62-68% in

Mrinalini Dey DrMiniDey

1 year 3 months ago
2-year #MANDARA data: Benralizumab shows durable remission, eosinophil suppression & OGC-sparing in EGPA. ~62-68% in remission at wk104. Low relapse rate, no loss of asthma control or decline of lung function. No new safety signals. @RheumNow #EULAR2025 #OP0166 https://t.co/kXh2q2ilJF
Difficult-to-treat & early PsA at #EULAR2025

GRAPPA definitions: D2T-PsA (≥3 therapies incl ≥2 b/tsDMARDs with

Antoni Chan MD (Prof) synovialjoints

1 year 3 months ago
Difficult-to-treat & early PsA at #EULAR2025 GRAPPA definitions: D2T-PsA (≥3 therapies incl ≥2 b/tsDMARDs with persistent inflammation); C2M-PsA (broader: comorbidities, pain, intolerance). 95% GRAPPA consensus. Abstact OP0175 @RheumNow #EULAR2025 https://t.co/eqKmMPh80x
Leeds study of 223 ACPA+ Arthralgia pts w quant. MRI of hand showing tenosynovitis (34% at baseline) doubled the risk o

Dr. John Cush RheumNow

1 year 3 months ago
Leeds study of 223 ACPA+ Arthralgia pts w quant. MRI of hand showing tenosynovitis (34% at baseline) doubled the risk of progression to RA. Total tenosynovitis Volume = incr. RA risk #EULAR2025 POS0472 https://t.co/eT0wbhp1uN
▶️Erosive hand OA

🔺Gull-wing erosion @ DIPJs ✅
🔺Saw-tooth erosions @ PIPJs ✅

#OA #Osteoarthritis #EULA

Dr Gurdeep S Dulay gurdeep_dulay

1 year 3 months ago
▶️Erosive hand OA 🔺Gull-wing erosion @ DIPJs ✅ 🔺Saw-tooth erosions @ PIPJs ✅ #OA #Osteoarthritis #EULAR2025 https://t.co/5Hh4Ki9P8V
Fast track PMR clinics in Denmark led to more patients seen, and time to referral went down.

If we don’t get in early

David Liew drdavidliew

1 year 3 months ago
Fast track PMR clinics in Denmark led to more patients seen, and time to referral went down. If we don’t get in early with a right diagnosis (and maybe early steroid-sparing) then PMR patients deteriorate. We shouldn’t let PMR be an end stage disease #EULAR2025 POS0136 @RheumNow https://t.co/pqwveamhJP
×